Skip to main content
OpenTrials
Completed

NCT Number: NCT03723694

Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

The purpose of this study is to test the effect of a cocoa-derived dietary flavanol on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. Th investigators will also examine the role of inflammation in this relationship.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Columbia University Irving Medical Center

New York, 10032, United States

About this study

Within 25 years, the US population aged 65 and over will double in size to 80 million bringing, with it an epidemic of aging-related cognitive decline, from normal cognitive aging to neurodegenerative disorders including Alzheimer's Disease. These conditions impair quality of life and functional status, impose an enormous burden on individuals, their families, the healthcare system, and require elucidation of mechanisms and development of new treatments to prevent or at least slow their progression. The use of plant-based food and drink for health purposes has a long and well-documented history. Cocoa beans contain a substance that has multiple beneficial health effects. In this study, the investigators will test the effect of this substance on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. The investigators also will examine the role of inflammation in this relationship. Such a trial has potential for significant clinical impact.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal screening or management of the subject).
  • Healthy Male or Female subjects. (Females must be post-menopausal)
  • Age between 50 and 69 years, both inclusive.
  • Body mass index between 18.0 and 35 kg/m², both inclusive.

Exclusion criteria

  • Currently undergoing medical treatment, including prescription drugs/medication.
  • Clinically significant abnormal hematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator.
  • History or presence of cancer (except basal cell skin cancer or squamous cell skin cancer), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception euthyroid struma), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders as judged by the Investigator.
  • Seated blood pressure at screening (after resting for 5 min in seated position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine heart rate outside the range 50-90 beats per minute. Measurement taken at consent before eligibility is determined
  • Heart Diseases.
  • Hepatitis B or C positive status.
  • HIV positive status.
  • History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  • Use of non-prescription medication, herbal products or nutritional supplements during the study, and within the last 4 weeks before the start of the study (screening), as judged by the Investigator; occasional use of aspirin, ibuprofen, acetaminophen is permitted.
  • Adherence to a vegan or vegetarian diet or to specialty/uncommon diets.
  • Food Allergies to tree nuts, soy, cocoa and cocoa-containing products.
  • People who choose to avoid caffeine intake.
  • Current or history of alcoholism or drug/chemical abuse as per Investigator's judgment.
  • Hormone Replacement Therapy; Currently pregnant; Pregnant or Interview\\ lactating within past 6 months; Hormonal birth control (pill).
  • Smoking.
  • Unwilling to have blood drawn or anxiety/nausea during a blood draw.
  • Uncomfortable completing memory and attention tasks in the English language
  • Montreal Cognitive Assessment (MoCA) score less than 26.
  • Inability to swallow study capsules Interview (at Consent)
  • Did not complete the two weeks Run-In Period (Participants who missed more than 2 intake occasions out of 14 days (28 occasions total) or if there are > 8 capsules left in the bottle after the two weeks will be excluded).

MRI RELATED

  • Cardiac Pacemaker
  • Internal Pump
  • Insulin Pump
  • Tattoo eyeliner
  • Wire sutures
  • Internal Metal Objects
  • Metal Slivers in Eye
  • Prosthesis
  • Hearing Aid Implants
  • Neurostimulator
  • Metal Fragments
  • Brain Aneurysm Clips
  • Vascular Clips
  • Breast Expander
  • Vena Cava Filter
  • Heart Valve
  • Metal Stents
  • Asthmatic symptoms within the past 3 years
  • Sickle Cell Disease

Treatment and study plan

650 mg of Cocoapro flavanols

Dietary Supplement

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.

0 mg of Cocoapro flavanols

Dietary Supplement

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.

Primary outcomes

  1. HMGB1

    Time frame: 12 weeks

    circulating levels of the inflammatory marker HMGB1

Secondary outcomes

  1. NFkB

    Time frame: 12 weeks

    TLR4-dependent NFkB

  2. TNFa

    Time frame: 12 weeks

    TLR4-dependent TNFa

Other outcomes

  1. ModBent

    Time frame: 12 weeks

    modified Benton Recognition Task

  2. ModRey

    Time frame: 12 weeks

    Modified Rey Auditory Verbal Learning Test

  3. multiple cognitive domains

    Time frame: 12 weeks

    NIH Toolbox Cognition Battery, which includes adaptive computerized tests of executive function, attention, episodic memory, language, processing speed, and working memory

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Oct 29, 2018
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.